← Back to Clinical Trials
Recruiting NCT03720197

NCT03720197 Registry of Patients Living With Type 1 Diabetes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03720197
Status Recruiting
Phase
Sponsor Institut de Recherches Cliniques de Montreal
Condition Type 1 Diabetes Mellitus
Study Type OBSERVATIONAL
Enrollment 6,000 participants
Start Date 2019-02-20
Primary Completion 2027-03-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Online questionnaire - Phase 1Online questionnaire - Phase 2Online questionnaire - Phase 3

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 6,000 participants in total. It began in 2019-02-20 with a primary completion date of 2027-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A registry of individuals with type 1 diabetes open to all patients with type 1 diabetes living in Canada will be established. The objective of this registry will be to measure the frequency and the severity of episodes of hypoglycemia. Participants will be invited to answer questionnaires about the frequency of their hypoglycemic episodes, their fear about hypoglycemia, their symptoms of hypoglycemia, the factors in cause (insulin therapy, nutrition, exercise, etc.), etc. Participation to the registry is divided in 3 phases. The first phase is mandatory for all participants. Phases 2 and 3 are optional.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of type 1 diabetes * Living in Canada Exclusion Criteria: * Type 2 diabetes * Gestational diabetes

Contact & Investigator

Central Contact

Virginie Messier

✉ virginie.messier@ircm.qc.ca

📞 514-987-5500

Principal Investigator

Remi Rabasa-Lhoret

PRINCIPAL INVESTIGATOR

Institut de Recherches Cliniques de Montreal

Frequently Asked Questions

Who can join the NCT03720197 clinical trial?

This trial is open to participants of all sexes, studying Type 1 Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03720197 currently recruiting?

Yes, NCT03720197 is actively recruiting participants. Contact the research team at virginie.messier@ircm.qc.ca for enrollment information.

Where is the NCT03720197 trial being conducted?

This trial is being conducted at Edmonton, Canada, Montreal, Canada, Montreal, Canada, Montreal, Canada and 3 additional locations.

Who is sponsoring the NCT03720197 clinical trial?

NCT03720197 is sponsored by Institut de Recherches Cliniques de Montreal. The principal investigator is Remi Rabasa-Lhoret at Institut de Recherches Cliniques de Montreal. The trial plans to enroll 6,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology